Risk prediction in acute coronary syndrome from serial in-hospital measurements of N-terminal pro-B-type natriuretic peptide

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

There is limited information about the in-hospital plasma profile of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with non-ST-elevation acute coronary syndrome (NSTACS) and furthermore, the prognostic influence of the timing of NT-proBNP measurements in NSTACS is unsettled.

These subject matters are elucidated in this study composed of 455 patients with NSTACS (symptoms <24 h).

Who Took Part

The study group was 455 patients.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

NT-proBNP was measured at 0, 6, 12, 24, 36, 48, 72 and 96 h following admission.

What Was Measured

There is limited information about the in-hospital plasma profile of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with non-ST-elevation acute coronary syndrome (NSTACS) and furthermore, the prognostic influence of the timing of NT-proBNP measurements in NSTACS is unsettled.

PubMed files the paper under topics including Acute Coronary Syndrome, Electrocardiography, Hospitalization, Natriuretic Peptide, Brain, Peptide Fragments, Risk Assessment and Troponin T.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 455 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Acute cardiac care), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.